Substance / Medication

Nateglinide

Overview

Active Ingredient
nateglinide
RxNorm CUI
274332

Indications

Nateglinide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Nateglinide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Labeler: Golden State Medical Supply, Inc.Updated: 2025-04-15T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Nateglinide tablets are contraindicated in patients with a history of hypersensitivity to nateglinide or its inactive ingredients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

903 trials linked to this intervention

903
Total Trials
103
Recruiting
282
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus.
Naushad Shaik Mohammad, Hussain Tajamul, Alrokayan Salman A et al. · Pharmacol Rep · 2022
PMID: 35932448Meta-Analysis
Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
Del Prato Stefano, Heine Robert J, Keilson Leonard et al. · Diabetes Care · 2003
PMID: 12832316Meta-Analysis
Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control.
Mita Tomoya, Watada Hirotaka, Shimizu Tomoaki et al. · Arterioscler Thromb Vasc Biol · 2007
PMID: 17872451RCT
Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou Jian, Deng Zixuan, Lu Jingyi et al. · Diabetes Technol Ther · 2015
PMID: 25781235Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nateglinide (substance)
SNOMED CT
387070004
UMLS CUI
C0903898
RxNorm CUI
274332
Labeler
Golden State Medical Supply, Inc.

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
903
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Nateglinide — Conditions, Biomarkers & Specialists | Healos | Healos